U.S. stock market update: Zhengye Biotechnology up 13.59%

U.S. Stock Market Midday Update Stocks with High Trading Volume in the Industry Eli Lilly fell 0.09%, with a trading volume of $1.344 billion. Based on recent important news: On September 29, Eli Lilly's progress in Alzheimer's treatment attracted market attention. Leerink expects that if Novo Nordisk's trial data is positive, Eli Lilly's stock price could rise by up to 10%. On September 28, Eli Lilly announced that the FDA approved its oral estrogen receptor antagonist Inluriyo for the treatment of certain types of breast cancer, driving stock price volatility. On September 27, Eli Lilly halted the mid-stage trial of bimagrumab for strategic business reasons, leading to a 3.1% drop in stock price. The pharmaceutical industry is facing tariff and drug pricing pressures. Novo Nordisk fell 0.52%. According to recent important news: On September 29, Morgan Stanley downgraded Novo Nordisk's rating to "Underweight," lowering the target price from $59 to $47, causing a pre-market drop of 3% in stock price. Morgan Stanley's rating adjustment had a significant impact on market sentiment. Data source: Morgan Stanley. On September 29, Novo Nordisk resubmitted its application for Awiqli for the treatment of type 2 diabetes to the U.S. Food and Drug Administration. This move may have a positive impact on the company's future market performance. Data source: Novo Nordisk. On September 27, European stocks rose as better-than-expected U.S. personal consumption expenditure data boosted investor sentiment, while Novo Nordisk's stock price fell by 3.5%. Policy uncertainty remains a potential pressure on the pharmaceutical sector. Data source: Bank J. Safra Sarasin. The pharmaceutical sector faces policy pressures, and market volatility is significant. Johnson & Johnson rose 0.77%, with a trading volume of $709 million. Based on recent key news: On September 29, Johnson & Johnson announced that the U.S. FDA has approved TREMFYA® for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in children aged six and older. This milestone makes TREMFYA® the first and only IL-23 inhibitor approved for such pediatric indications, driving stock price up. On September 27, Johnson & Johnson's CEO expressed optimism about the future of drug innovation in the U.S. during an interview with CNBC, boosting market confidence. On September 29, Johnson & Johnson announced its dividend has increased for 63 consecutive years, further solidifying its position as a stable dividend stock, attracting investors. The pharmaceutical industry is performing well overall, with macroeconomic data supporting stock market gains. Stocks with High Market Capitalization in the Industry Novartis rose 0.23%, with a market capitalization of $239.9 billion. According to recent important news: On September 29, Novartis announced the launch of a tender offer to acquire the U.S. biopharmaceutical company Tourmaline Bio for $48 per share in cash. This move may enhance its competitiveness in the biopharmaceutical field, driving stock price up On September 29, Novartis plans to launch a direct-to-patient sales platform in the United States, offering a 55% discount on the Cosentyx drug, aimed at improving the accessibility and affordability of the medication, benefiting the company's market expansion. On September 27, Novartis announced it will invest $23 billion over the next five years to expand its facilities in the United States, which is expected to create over 1,000 jobs, demonstrating the company's long-term commitment to the U.S. market. The impact of policy changes in the pharmaceutical industry is significant